Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | FPR1 | P21462 | 1/20 | 0.30 |
| ▸ | FPR2 | P25090 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1619763 | 0.89 | MEN1 (0.36) | MEN1KMT2AMCL1RXFP1FPR1 | |
| SCHEMBL2872170 | 0.80 | MEN1 (0.35) | MEN1KMT2AMCL1RXFP1FPR1 | |
| SCHEMBL2701254 | 0.77 | ALDH1A1 (0.41) | MEN1KMT2AMCL1RXFP1FPR1 | |
| SCHEMBL2701454 | 0.75 | MEN1 (0.33) | MEN1KMT2AMCL1RXFP1FPR1 | |
| SCHEMBL1619764 | 0.68 | MEN1 (0.39) | MEN1KMT2AMCL1RXFP1FPR1 | |
| SCHEMBL2873245 | 0.65 | MEN1 (0.30) | MEN1KMT2AMCL1 | |
| SCHEMBL1621026 | 0.64 | ALDH1A1 (0.47) | MEN1KMT2AMCL1FPR1FPR2 | |
| SCHEMBL5883488 | 0.63 | MEN1 (0.42) | MEN1KMT2AMCL1RXFP1FPR1 | |
| SCHEMBL1620420 | 0.63 | NOS3 (0.34) | MEN1KMT2AMCL1ALDH1A1 | |
| SCHEMBL1618513 | 0.62 | MEN1 (0.37) | MEN1KMT2AMCL1RXFP1FPR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816522-B2 | Triazolone derivatives | EISAI CO., LTD. (JP) | 2010-10-19 | — | — | US | disclosed |
| US-20080015199-A1 | Triazolone derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015199-A1 | Triazolone derivatives | F3, F12, F2 | MEN1 335/4885KMT2A 1639/4885MCL1 538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.